ATE268594T1 - Phospholipid-beschichtete mikrokristalle für die kontrollierte abgabe von pharmakologisch aktiven verbindungen und verfahren zu deren herstellung und verwendung - Google Patents

Phospholipid-beschichtete mikrokristalle für die kontrollierte abgabe von pharmakologisch aktiven verbindungen und verfahren zu deren herstellung und verwendung

Info

Publication number
ATE268594T1
ATE268594T1 AT99971704T AT99971704T ATE268594T1 AT E268594 T1 ATE268594 T1 AT E268594T1 AT 99971704 T AT99971704 T AT 99971704T AT 99971704 T AT99971704 T AT 99971704T AT E268594 T1 ATE268594 T1 AT E268594T1
Authority
AT
Austria
Prior art keywords
microcrystals
active compounds
pharmacologically active
mum
phospholipide
Prior art date
Application number
AT99971704T
Other languages
English (en)
Inventor
Kenneth A Larson
William R Campbell
Douglas I Hepler
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Application granted granted Critical
Publication of ATE268594T1 publication Critical patent/ATE268594T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
AT99971704T 1998-11-10 1999-11-08 Phospholipid-beschichtete mikrokristalle für die kontrollierte abgabe von pharmakologisch aktiven verbindungen und verfahren zu deren herstellung und verwendung ATE268594T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/190,049 US6180136B1 (en) 1998-11-10 1998-11-10 Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
PCT/US1999/026452 WO2000027369A1 (en) 1998-11-10 1999-11-08 Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

Publications (1)

Publication Number Publication Date
ATE268594T1 true ATE268594T1 (de) 2004-06-15

Family

ID=22699828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99971704T ATE268594T1 (de) 1998-11-10 1999-11-08 Phospholipid-beschichtete mikrokristalle für die kontrollierte abgabe von pharmakologisch aktiven verbindungen und verfahren zu deren herstellung und verwendung

Country Status (9)

Country Link
US (2) US6180136B1 (de)
EP (1) EP1043978B1 (de)
JP (1) JP3831613B2 (de)
AT (1) ATE268594T1 (de)
AU (1) AU760111B2 (de)
CA (1) CA2315975C (de)
DE (1) DE69917883T2 (de)
ES (1) ES2221484T3 (de)
WO (1) WO2000027369A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
ES2211151T3 (es) * 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
DE60000622T2 (de) * 1999-06-10 2003-02-27 Max Planck Gesellschaft Einkapselung von kristallen mit mehrschichtigem überzug
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US6955908B1 (en) * 2000-06-21 2005-10-18 Lambl Barbara B Organism associated with nongonococcal urethritis
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
IN188924B (de) * 2001-03-01 2002-11-23 Bharat Serums & Vaccines Ltd
DE10139965B4 (de) * 2001-08-14 2005-12-29 Biotest Ag Gammasterilisierbares Kulturmedium zum Nachweis von Hefen und Pilzen
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US6936273B2 (en) * 2002-12-20 2005-08-30 Idexx Laboratories, Inc. Liposomal analgesic formulation and use
DE602004016292D1 (de) * 2003-01-20 2008-10-16 Auriga Internat S A Verwendung einer zusammensetzung mit vitamin k1-oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
EP1568369A1 (de) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam zur Behandlung von Atemwegserkrankungen bei Schweinen
DE102004013637A1 (de) * 2004-03-19 2005-10-13 Capsulution Nanoscience Ag Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
BRPI0515181A (pt) * 2004-09-13 2008-07-22 Bharat Serums & Vaccines Ltd composição de óleo-em-água estéril para administração intravenosa, uso de um monoglicerìdeo e processo de preparação de uma composição para administração intravenosa
EP1871365A2 (de) * 2005-04-12 2008-01-02 Romark Laboratories, L.C. Verfahren zur behandlung von erkrankungen durch hemmung der funktion von molekularen chaperonen wie protein disulfid-isomerasen, diese enthaltende pharmazeutische zusammensetzungen und screening-verfahren zur identifizierung von therapeutischen mitteln
JP2009510007A (ja) * 2005-09-30 2009-03-12 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む医薬調製
ES2422556T3 (es) * 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
CN102647971B (zh) 2009-10-12 2016-03-16 贝林格尔.英格海姆维特梅迪卡有限公司 用于包含美洛昔康的组合物的容器
AU2010347598B2 (en) 2010-03-03 2014-11-27 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CN102302456B (zh) * 2011-07-26 2014-03-12 武汉回盛生物科技有限公司 一种动物专用磷酸替米考星微球的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528193A (en) * 1978-12-27 1985-07-09 A. Natterman & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
DE2914788A1 (de) 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
DE3022136C2 (de) * 1980-06-13 1986-07-17 A. Nattermann & Cie GmbH, 5000 Köln Verfahren zum Abfüllen von Phospholipide enthaltenden pharmazeutischen Massen in Hartkapseln
US4847015A (en) * 1986-02-10 1989-07-11 Kewpie Kabushiki Kaisha Process for producing egg yolk lecithin having reduced PE content and/or containing substantially no impurities
DE3608455A1 (de) * 1986-03-14 1987-09-17 Nattermann A & Cie Phospholipidhaltige produkte, deren herstellung und verwendung
CA1338736C (fr) 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
JPH01131189A (ja) * 1987-11-17 1989-05-24 Nippon Oil & Fats Co Ltd ドコサヘキサエン酸含有リン脂質の製造法
JPH02132736A (ja) 1988-11-14 1990-05-22 Toshiba Corp 大電力クライストロン
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material

Also Published As

Publication number Publication date
EP1043978B1 (de) 2004-06-09
AU1473500A (en) 2000-05-29
AU760111B2 (en) 2003-05-08
JP2002529400A (ja) 2002-09-10
DE69917883T2 (de) 2005-06-02
EP1043978A1 (de) 2000-10-18
WO2000027369A1 (en) 2000-05-18
CA2315975A1 (en) 2000-05-18
CA2315975C (en) 2009-01-13
ES2221484T3 (es) 2004-12-16
US6180136B1 (en) 2001-01-30
US6423338B1 (en) 2002-07-23
JP3831613B2 (ja) 2006-10-11
DE69917883D1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
ATE268594T1 (de) Phospholipid-beschichtete mikrokristalle für die kontrollierte abgabe von pharmakologisch aktiven verbindungen und verfahren zu deren herstellung und verwendung
DE3873410D1 (de) Formulierung zur oralen arzneistoffabgabe, sowie verfahren zu deren herstellung.
CY1112892T1 (el) Δισκιο λασοφοξιφαινης και επικαλυψη του
DE60023841D1 (de) Verfahren zur herstellung alkylierter salicylamide
BR9808429A (pt) Composição farmacêutica e processo para a sua preparação.
DE122004000032I2 (de) Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
ATE378062T1 (de) Mischmicell-arzneistoffverabreichungssystem und verfahren zu dessen herstellung
ATE204466T1 (de) Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung
HUP0203198A2 (hu) Tramadolvegyület és görcsoldó hatóanyagot tartalmazó gyógyászati készítmény, eljárás az előállítására és alkalmazása
DE60130139D1 (de) Zahnärztliche fräsrohlingsanordnung sowie verfahren zu deren herstellung
TR201910177T4 (tr) Bir sinakalset HCl içeren hızlı çözünme formülasyonu.
MXPA05008382A (es) Acidos grasos, gliceridos y analogos con longitud de cadena media como estimuladores de eritropoyesis.
FR2816507B1 (fr) Microgranules a base de principe actif, procede de fabrication et compositons pharmaceutiques integrant lesdits microgranules
DE69510928D1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
BR0110618A (pt) Composição farmacêutica similar a gel para administraçâo subcutânea compreendendo ácidos bis-fosfÈnicos ou seus sais
AR020780A1 (es) Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
CA2355077A1 (en) Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
WO2008087323A8 (fr) Forme galenique pour l'administration par voie trans-muqueuse de paracetamol
HUP0402323A2 (hu) Savval szemben instabil gyógyhatású vegyületeket tartalmazó preparatív készítmények és eljárás előállításukra
DE50108114D1 (de) Mikropartikel mit verbessertem freisetzungsprofil und verfahren zu deren herstellung
DE60203881D1 (de) Verfahren zum herstellen von körperpflegemitteln
DE50208851D1 (de) Gelierzucker und verfahren zu dessen herstellung
DE69911224D1 (de) Geschmacksmaskierte kautablette mit sofortiger wirkstofffreisetzung sowie herstellungsverfahren
IT1272990B (it) "composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione".

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties